Latest news and insights on the pharmaceutical industry | Indian Pharma Post | Page 186

Results For "ITU"

1917 News Found

Scientists from BRICS work on genomic sequencing of Covid-19
Drug Approval | August 06, 2021

Scientists from BRICS work on genomic sequencing of Covid-19

Whole-genome sequencing to identify genetic mutation; epidemiological studies to help assess the distribution and mathematical modelling to forecast spread


Covaxin receives approval from Hungary
Biotech | August 05, 2021

Covaxin receives approval from Hungary

More countries recognise Covaxin


NPPA issues notice to manufacturers and importers of knee implants
Policy | August 05, 2021

NPPA issues notice to manufacturers and importers of knee implants

The data should be submitted by August 12th 2021


Biotech-PRIDE guidelines released
Biotech | August 05, 2021

Biotech-PRIDE guidelines released

Releasing it, Union Minister Jitendra Singh said India needs its database for Indian research and solutions.


Govt committed to recognise healthcare workers engaged in Covid-19
Policy | August 04, 2021

Govt committed to recognise healthcare workers engaged in Covid-19

Five seats reserved for Wards of COVID warriors in central MBBS admission


Abbott receives FDA clearance for its imaging tech using AI
Digitisation | August 04, 2021

Abbott receives FDA clearance for its imaging tech using AI

Ultreon 1.0 Software, the first-of-its-kind imaging software, merges optical coherence tomography with the power of automation using AI -


Mindpeers launches on-demand behavioural healthcare platform
Healthcare | August 04, 2021

Mindpeers launches on-demand behavioural healthcare platform

It is designed to tackle mental health issues


AYUSH 64 effective in mild and moderate COVID 19
Drug Approval | August 03, 2021

AYUSH 64 effective in mild and moderate COVID 19

It works as an adjunct to standard care based on robust clinical trials


Ajanta Pharma aims to file 10-12 ANDAs per annum
News | August 02, 2021

Ajanta Pharma aims to file 10-12 ANDAs per annum

India business is growing as per projections; whereas US business will bounce back soon.


Granules India earmarks Rs 400 crore as Capex for FY 22
News | August 02, 2021

Granules India earmarks Rs 400 crore as Capex for FY 22

The company has an outlay of Rs 120-140 crore as R & D expense for FY 22